R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.

Biotech Giants' R&D Spending: Alnylam vs. Apellis

__timestampAlnylam Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.
Wednesday, January 1, 20141902490008379522
Thursday, January 1, 201527649500013730311
Friday, January 1, 201638239200022978599
Sunday, January 1, 201739063500040303878
Monday, January 1, 2018505420000105285576
Tuesday, January 1, 2019655114000220968770
Wednesday, January 1, 2020654819000299921000
Friday, January 1, 2021792156000420869000
Saturday, January 1, 2022883015000387236000
Sunday, January 1, 20231004415000354387000
Monday, January 1, 20241126232000
Loading chart...

In pursuit of knowledge

The R&D Race: Alnylam vs. Apellis

In the dynamic world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Alnylam Pharmaceuticals and Apellis Pharmaceuticals, two prominent players in the industry, have shown distinct trajectories in their R&D investments over the past decade.

Alnylam's Steady Ascent

Since 2014, Alnylam has consistently increased its R&D spending, culminating in a remarkable 428% growth by 2023. This upward trend underscores Alnylam's dedication to pioneering RNA interference therapeutics, a field where it has established itself as a leader.

Apellis' Rapid Growth

Apellis, while starting from a smaller base, has demonstrated an impressive 4,130% increase in R&D expenses over the same period. This surge reflects its aggressive pursuit of novel treatments for rare diseases, positioning it as a formidable contender in the biotech arena.

Both companies exemplify the relentless pursuit of innovation, each carving its niche in the competitive landscape of pharmaceutical research.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025